Atossa Genetics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Beats Expectations By $0.30 EPS

Atossa Genetics (NASDAQ:ATOS) released its earnings results on Tuesday. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.30, FiscalAI reports.

Atossa Genetics Stock Performance

Atossa Genetics stock traded up $0.10 during midday trading on Tuesday, reaching $2.23. 33,170 shares of the company were exchanged, compared to its average volume of 112,619. The firm’s 50-day simple moving average is $2.37 and its 200-day simple moving average is $3.78. Atossa Genetics has a 1 year low of $1.70 and a 1 year high of $14.85. The company has a market capitalization of $22.21 million, a price-to-earnings ratio of -0.72 and a beta of 1.38.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Atossa Genetics in a research report on Tuesday, September 8th. Wall Street Zen upgraded Atossa Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.33.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.